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Glucagon, an essential regulator of glucose homeostasis, also
modulates lipid metabolism and promotes weight loss, as
reflected by the wasting observed in glucagonoma patients.
Recently, coagonist peptides that include glucagon agonism have
emerged as promising therapeutic candidates for the treatment of
obesity and diabetes. We developed a novel stable and soluble
glucagon receptor (GcgR) agonist, which allowed for in vivo
dissection of glucagon action. As expected, chronic GcgR agonism
in mice resulted in hyperglycemia and lower body fat and plasma
cholesterol. Notably, GcgR activation also raised hepatic expres-
sion and circulating levels of fibroblast growth factor 21 (FGF21).
This effect was retained in isolated primary hepatocytes from wild-
type (WT) mice, but not GcgR knockout mice. We confirmed this
link in healthy human volunteers, where injection of natural
glucagon increased plasma FGF21 within hours. Functional
relevance was evidenced in mice with genetic deletion of
FGF21, where GcgR activation failed to induce the body weight
loss and lipid metabolism changes observed in WT mice. Taken
together, these data reveal for the first time that glucagon controls
glucose, energy, and lipid metabolism at least in part via FGF21-
dependent pathways. Diabetes 62:1453–1463, 2013
R
eleased during periods of hypoglycemia, gluca-
gon is the key counter-regulatory hormone op-
posing insulin action. Identified in the 1920s,
glucagon is secreted by pancreatic a-cells (1) and
encoded by the proglucagon gene. Glucagon is best known
for its stimulation of hepatic glucose production by
increasing glycogenolysis and gluconeogenesis, while
simultaneously inhibiting glycogen synthesis. Accordingly,
unopposed glucagon signaling is a crucial pathophysiologi-
cal component of diabetes and thus has been widely studied
(2–6). However, glucagon action regulates a far greater
range of physiological processes, including lipolysis, keto-
genesis, fatty acid oxidation, satiation, thermogenesis, en-
ergy expenditure (EE), and bile acid metabolism. Recent
studies have revealed that when coupled with glucagon-like
protein 1 (GLP-1) agonism, glucagon action may offer pre-
viously unrecognized therapeutic opportunities for the
metabolic syndrome (7,8). Although such provocative find-
ings have renewed interest in glucagon research, the mo-
lecular underpinnings of these effects remained elusive.
Glucagon is only one of several fasting hormones. It is
thus possible that one, or several, other hormone(s) with
a metabolic role during fasting is regulated by, or mediates
a portion of, glucagon’s effects. Among these fasting-induced
hormones is fibroblast growth factor 21 (FGF21), which
has recently received considerable attention (9). FGF21
expression and secretion are elicited in the liver during
periods of fasting (10–12) and may be induced by down-
stream signaling of glucagon (8,13). Recent studies suggest
that, like glucagon, FGF21 signaling regulates glucose,
lipid, cholesterol, and bile acid metabolism (14,15), impli-
cating FGF21 as an attractive drug candidate for metabolic
disease. We report here that FGF21 mediates the key
metabolic actions of glucagon.
RESEARCH DESIGN AND METHODS
Synthesis of a novel glucagon receptor agonist (IUB288). 0.2 mmol Boc
Thr(Bzl)-Pam resin was the initial synthetic substrate upon which the target
peptide was assembled through repetitive DEPBT/diisopropylethylamine
(DIEA) activated single couplings on a CSBio336 peptide synthesizer (7). The
assembled peptide resin was treated with 20% piperidine/dimethylformamide
(DMF) at room temperature for 10 min to remove the side-chain Fmoc pro-
tection. The resin was filtered and washed with DMF, and an activated solu-
tion of Fmoc Glu-aOBzl was added to acylate the Lys10 side chain (previously
prepared by dissolving FmocGlu-aBzl[Aapptec] in 0.5 mol/L DEPBT/DMF and
subsequently adding DIEA). After 1 h, the resin was filtered and washed with
DMF. The above process was repeated using an equivalent aliquot of Fmoc
Glu-aOBzl and once more with 2.0 mmol palmitic acid (Sigma, St. Louis, MO).
The completed peptide resin was filtered, washed, treated with 50% trifluoro-
acetic acid/dichloromethane, and neutralized with 5% DIEA/dichloromethane.
The peptide was cleaved from the resin in liquid hydrogen fluid in the presence
of p-cresol at 0°C, for 1 h. The peptide was solubilized in 50% aqueous
acetonitrile, diluted with dilute ammonium bicarbonate, and purified by
Amberchrom XT20 chromatography with a linear gradient of aqueous acetoni-
trile in 0.025 mol/L ammonium bicarbonate. The pure peptide of the sequence
HaibQGTFISDK(rErE-C16)SKYLDaibRAAQDFVQWLMDT was identified by
analytical high-performance liquid chromatography and electrospray ioniza-
tion mass spectral analysis; theoretical molecular weight = 3,868.4 g/mol and
observed mass = 3,867.5 g/mol.
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Reporter gene assay. The relative receptor potency at the glucagon and GLP-
1 receptor was determined by the ability of IUB288 to induce cAMP and was
measured in a firefly luciferase-based reporter gene assay as previously de-
scribed (7). In brief, HEK293 cells cotransfected with either glucagon or the
GLP-1 receptor and the luciferase gene linked to the cAMP-responsive ele-
ment were used (7). The cells were serum deprived by culturing for 16 h in
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented
with 0.25% bovine growth serum (HyClone, Logan, UT) and then incubated with
serial dilutions of either glucagon, GLP-1, or IUB288 for 5 h at 37°C, 5% CO2 in
96-well poly-D-lysine–coated Biocoat plates (BD Biosciences, San Jose, CA). At
the end of the incubation, 100 mL of LucLite luminescence substrate reagent
(Perkin Elmer, Wellesley, MA) was added to each well. The plate was shaken
briefly and incubated for 10 min in the dark, and light output was measured on
a MicroBeta-1450 liquid scintillation counter (PerkinElmer, Wellesley, MA).
Glucagon challenge in man. In a double-blind crossover design, obese
healthy subjects (five men: 29.46 2.6 years of age and BMI = 33.96 1.6 kg/m2)
received 1 mg of glucagon (GlucaGen; Novo Nordisk Pharma Inc., Bagsværd,
Denmark) intramuscularly. The test was performed as detailed previously
(16). Serum FGF21 levels were determined by radioimmunoassay (Phoenix
Europe GmbH, Karlsruhe, Germany).
Animal models. FGF21-deficient mice were generated as previously described
(17) and maintained in our facilities on a C57Bl/6J (Jackson Laboratories)
background. All mice were fed a standard chow (Teklad LM-485, 5.6% fat) or
high-fat diet (HFD; 58.0 kcal % fat; D12331 Research Diets, New Brunswick,
NJ). db/db mice were obtained from Jackson Laboratories. Glucagon receptor
(GcgR)–deficient mice were obtained from Deltagene (San Mateo, CA). Mice
were single or group housed on a 12:12-h light-dark cycle (light on from
0600 to 1800 h) at 22°C and constant humidity with free access to food and
water, except as noted. All studies were approved by and performed according
to the guidelines of the Institutional Animal Care and Use Committee of the
University of Cincinnati.
Body composition measurements. Whole-body composition (fat and lean
mass) was measured using noninvasive nuclear magnetic resonance technol-
ogy (EchoMRI, Houston, TX).
IUB288 pharmacokinetics. Two male C57Bl/6J mice were fasted and then
injected subcutaneously with 10 nmol/kg IUB288. Plasma samples were col-
lected 1, 3, 5, 7, and 24 h after injection, and IUB288 concentrations were
determined by liquid chromatography–mass spectrometry, pharmacokinetics
calculations by Biobook (IDBS e-workbook Suite 8.2.0).
Glucose and insulin tolerance tests. Intraperitoneal glucose and insulin
tolerance tests were performed by injection of glucose (2 g/kg, 20% wt/vol
D-glucose [Sigma] in 0.9% wt/vol saline) or human regular insulin (0.75 units/
kg [Lilly Humalog] in 0.9% wt/vol saline) to 6-h fasted mice. Blood samples
were collected immediately before and 15, 30, 45, 60, 90, and 120 min after
injection. Blood glucose was determined with a TheraSense Freestyle
glucometer.
Hormone measurements. Plasma insulin, GLP-1, and glucagon were deter-
mined using Meso Scale Discovery MULTI-ARRAY Assay System (Meso Scale
Discovery, Gaithersburg, MD). IUB288 concentrations from 0.2 pmol/mL to
200 nmol/mL were undetectable using this assay (data not shown), suggesting
that there was no cross-reactivity with the injected compound. Plasma FGF21
was analyzed individually by ELISA assay (EZRMFGF21–26 K; Millipore,
Billerica, MA). Plasma leptin was measured via Luminex. Plasma trigly-
cerides, nonesterified free fatty acids (NEFAs), ketone bodies, and choles-
terol levels were analyzed individually by enzymatic assay (Thermo Electron,
Waltham, MA, and Wako Diagnostic, Richmond, VA).
EE and locomotor activity. EE and home-cage activity were assessed using
a combined indirect calorimetry system (TSE Systems, Chesterfield, MO) as
previously described (18). O2 consumption and CO2 production were mea-
sured every 10 min to determine the respiratory quotient and EE. Home-cage
locomotor activity was determined using a multidimensional infrared light-
beam system expressed as beam breaks.
FIG. 1. Characteristics of the GcgR agonist IUB288. A: IUB288 chemical structure. Activity of IUB288 at the GcgR (B) and GLP-1 receptor (C) in
cultured HEK293 cells. Dose-normalized bioavailability of IUB288 (D) after a single subcutaneous injection (10 nmol/kg) in C57Bl/6J mice (displayed
as the mean of n = 2). Blood glucose excursion (E) in response to an acute IUB288 challenge (10 nmol/kg) in lean, chow-fed, male C57Bl/6J mice (n = 8
per treatment). All data are represented as mean 6 SEM. ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis.
FGF21 MEDIATES CHRONIC GLUCAGON ACTION
1454 DIABETES, VOL. 62, MAY 2013 diabetes.diabetesjournals.org
Gene expression.Mice were decapitated without anesthesia, and trunk blood
and tissues were collected immediately. Tissues were frozen on dry ice and
stored at 280°C. RNA was isolated using the RNeasy Lipid Mini-Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. cDNA was syn-
thesized by reverse transcription PCR using SuperScriptIII, DNase treatment,
and anti-RNase treatment (Invitrogen, Carlsbad, CA). Single-gene qPCR was
performed according to the manufacturer’s instructions on a 7900 real-time
PCR machine (Applied Biosystems, Foster City, CA). Data were normalized to
the housekeeping gene 18s and expressed as fold change.
Cell culture. Primary hepatocytes were isolated as previously described (19).
Rat H4IIE cells purchased from American Type Culture Collection (Manassas,
VA) were cultured in Eagle’s minimum essential medium (4.5 g/L glucose)
containing 1% FBS (HyClone Laboratories, Grand Island, NY) and antibiotics
(penicillin, 75 mg/mL; streptomycin, 50 mg/mL) in 5% CO2/95% air at 37°C.
Treatments were conducted when H4IIE cells reached 90% confluence in six-
well plates.
Statistics. All data are represented as mean and SEM. Significance was de-
termined by one-way or two-way ANOVA with Bonferroni multiple comparison
posttest and, when appropriate, by unpaired Student t test. All statistics were
performed using GraphPad Prism version 5.0 for Windows (GraphPad Soft-
ware, San Diego, CA). Statistical significance was assumed when P , 0.05.
RESULTS
Development of a potent, soluble, long-acting, and
selective GcgR agonist. Although discovered in the early
1920s, the native structure of glucagon has hindered in-
depth investigation of its biology, as it does not easily lend
itself to mechanistic pharmacological studies due to its
low aqueous solubility (20) and its propensity to form
amyloid-like fibrils (21). The dissection of functional
interactions between glucagon and FGF21 in the regula-
tion of systems metabolism therefore required the gener-
ation of a long-acting, soluble, and highly selective GcgR
agonist. This objective was fulfilled by subtle modification
of the glucagon sequence that extended its duration
of action while maintaining selectivity. The chemical
structure of IUB288 (HaibQGTFISDK[rErE-C16]SKYLDai-
bRAAQDFVQWLMDT) differs from native glucagon at six
positions (Fig. 1A). Collectively, the in vitro receptor
profile of this acylated glucagon agonist is shown in Fig.
1B and C, where IUB288 demonstrates activity sizably
enhanced relative to native glucagon and a selectivity of
approximately 100-fold at the GLP-1 receptor.
Subcutaneous injection (10 nmol/kg) of this GcgR ago-
nist in naive C57Bl/6J mice resulted in a prolonged bio-
availability over 24 h (Fig. 1D), with similar results
observed in rats (data not shown). Peak concentration
(Cmax) and mean estimated terminal elimination half-life
(t1/2, z) at this dose were observed to be 17 ng/mL and 6.3
h, respectively. Further confirming its in vivo efficacy, in-
traperitoneal injection (10 nmol/kg) in C57Bl/6J mice sig-
nificantly increased t = 15 and 30 min, as well as overall
blood glucose (P = 0.0104) (Fig. 1E). Taken together, these
data suggest that IUB288 is a potent, long acting, and se-
lective GcgR agonist that may allow in vivo inspection of
chronic GcgR signaling.
GcgR agonism promotes negative energy balance in
DIO mice. To investigate the effect of chronically in-
creased GcgR signaling on energy metabolism, we com-
pared several levels of GcgR activation in DIO mice. GcgR
agonism lowered body weight and food intake, with a sig-
nificant decrease observed at an agonist dose of 10
nmol/kg (Fig. 2A and B).
The ad lib blood glucose in these mice increased in
a dose-dependent manner (Fig. 2C and D). We next
assessed the effect of chronic GcgR agonism in age-
matched chow-fed and DIO mice. Daily treatment of these
mice (10 nmol/kg/day) decreased body and fat mass in DIO
but not in lean mice (Fig. 3A and B and Supplementary Fig.
1G). Food intake in the standard chow-fed mice was
elevated (day 16, P , 0.05) after chronic GcgR activation
as compared with vehicle-treated mice (Fig. 3C). Con-
versely, in DIO mice receiving chronic GcgR activation,
there was no difference in food intake (Fig. 3C). In addi-
tion to its effects on body weight and fat mass, GcgR
agonism rescued hypercholesterolemia, but not the
FIG. 2. Dose-dependency study of chronic GcgR activation. Body weight (A), food intake (B), and ad libitum blood glucose (C and D) in response to
vehicle (PBS, ○) or 0.3 (●), 1.0 (□), 3.0 (■), or 10 nmol/kg/day (△) IUB288. All treatments were conducted in 11-month-old male C57Bl/6J mice
maintained on HFD for 9 months. All data are represented as mean 6 SEM; n = 8 per treatment. **P < 0.01; ***P < 0.001 vs. vehicle control,
two-way ANOVA with Bonferroni post hoc analysis. Lowercase letters (D) denote statistically similar (P > 0.05) groups, one-way ANOVA with
Bonferroni post hoc analysis.
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hypertriglyceridemia observed in DIO mice (Fig. 3D and
E). Consistent with the decrease in plasma cholesterol,
hepatic 3-hydroxy-3-methylglutaryl coenzyme-A reductase
(HMGCR) expression was suppressed by chronic GcgR
activation in DIO mice (Fig. 3F). Both chow-fed and DIO
groups demonstrated increased ad libitum blood glucose
and impaired glucose tolerance when treated with IUB288
(Supplementary Fig. 1A and B). Chronic GcgR activation
had no clear effect on plasma insulin, leptin, GLP-1, or
endogenous glucagon levels in DIO mice (Supplementary
Fig. 1C–F). Taken together, these data suggest that chronic
GcgR activation affects glucose homeostasis, lipidemia,
body weight, and food intake, although only the glycemic
regulation was dose dependent in nature.
Glucagon-stimulated body and fat mass loss is leptin
independent. To evaluate the role of leptin signaling in Gcg-
stimulated loss of body and fat mass, we administered GcgR
agonist to db/db mice for 7 days. Daily treatment of these
mice (10 nmol/kg/day) stimulated a decrease in body weight
(Fig. 4A and B) and increased core body temperature (Fig.
4C). Chronic GcgR agonism in hyperglycemic db/dbmice did
not affect ad lib or fasting blood glucose (Fig. 4D and E) but
enhanced insulin sensitivity, as assessed by glucose excur-
sion and rate of disappearance (Kd) during an intraperitoneal
insulin tolerance test (Fig. 4F and G). Food intake was not
different between treated and vehicle mice (Fig. 4H).
GcgR activation stimulates FGF21 expression and
secretion in vivo. The metabolic action profile of FGF21,
derived from the liver, pancreas, and adipose tissue (22),
significantly overlaps with that of glucagon. To dissect the
molecular mechanisms mediating the metabolic actions of
Gcg R agonism in vivo, we tested the hypothesis that FGF21
may play a relevant role. We observed that acute Gcg
Ractivation in DIO C57Bl/6J mice significantly increased
plasma FGF21 (Fig. 5A). Mirroring the bioavailability of our
GcgR agonist, this elevation in plasma FGF21 subsequently
returned to baseline levels, suggesting that acute GcgR ac-
tivation reversibly upregulates FGF21 secretion in rodents.
When continued for 16 days, chronic GcgR activation in-
creased both hepatic FGF21 expression (Fig. 5B) and
plasma FGF21 (Fig. 5C). These elevated FGF21 levels co-
incided with a robust decrease in body weight and fat mass,
as displayed in Fig. 2. These findings demonstrate that GcgR
agonism stimulates FGF21 expression and secretion in as-
sociation with glucagon-induced body and fat mass loss.
GcgR activation stimulates expression of FGF21 in
vitro. As hepatocytes express both GcgR and FGF21, we
next investigated if glucagon-stimulated FGF21 secretion
FIG. 3. Effects of chronic GcgR activation on energy balance and plasma lipids. Body weight (A), fat mass (B), and food intake (C) in response to
16 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment in standard chow– (circles) or HFD-fed (squares)
C57Bl/6J mice. Plasma concentrations of triglycerides (D) and cholesterol (E) and hepatic HMGCR expression (F) after 18 days of vehicle (PBS,
closed bars) or 10 nmol/kg/day IUB288 (open bars) in standard chow– or HFD-fed C57Bl/6J mice. All treatments were conducted in 11-month-old
male C57Bl/6J mice maintained on standard chow or HFD for 9 months. All data are represented as mean 6 SEM; n = 8 per treatment. A–C: *P <
0.05; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. D and E: ***P < 0.001 vs. vehicle control, one-way
ANOVA with Bonferroni post hoc analysis. F: *P < 0.05 vs. vehicle control, unpaired Student t test.
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could be induced in a cell-autonomous manner. We found
that glucagon dose-dependently increased FGF21 expres-
sion and secretion in wild-type (WT) hepatocytes, but not
GcgR knockout hepatocytes (Fig. 5D and E). Likewise,
GcgR activation in rat H-4IIE cells stimulated FGF21 ex-
pression (Fig. 5F), indicating that GcgR activation triggers
FGF21 production in a cell-autonomous manner.
Native glucagon stimulates FGF21 secretion in humans.
To evaluate if these results are clinically relevant, we next
administered native glucagon (1 mg) to 12 obese, healthy
human volunteers. Plasma FGF21 concentrations increased
significantly (Fig. 5G) after glucagon administration. In
contrast, plasma FGF21 concentrations slightly decreased
(240 min) after placebo administration. The area under the
curve for glucagon-induced FGF21 secretion over time
was significantly greater when compared with placebo
(Fig. 5H).
Protection from diet-induced obesity by chronic GcgR
activation requires FGF21. To test the hypothesis that
FGF21 mediates the metabolic effects of glucagon, we
FIG. 4. Effects of chronic GcgR activation in db/dbmice. Absolute (A) and relative body weight (B) of db/dbmice during 7 days of vehicle (PBS,■)
or 10 nmol/kg/day IUB288 (□) treatment. Body core temperature (C) on day 6 of vehicle (PBS,■) or 10 nmol/kg/day IUB288 (□). Ad libitum blood
glucose during chronic GcgR activation (D). Fasting blood glucose (6 h) (E) of db/db mice after 7 days of chronic GcgR activation. Blood glucose
excursion (F) and rate of disappearance (Kd, 0–45 min) during 0.75 units/kg insulin challenge (G) after 7 days of chronic GcgR activation in 6-h
fasted db/db mice. Cumulative food intake (H) of db/db mice (three cages of four mice per cage) during 7 days of vehicle (PBS, ■) or 10
nmol/kg/day IUB288 (open squares) treatment. All treatments were conducted in 12-week-old male db/db mice maintained on standard chow diet.
All data are represented as mean 6 SEM; n = 11–12 per treatment. A, B, and F: *P < 0.05; ***P < 0.001 vs. vehicle control, two-way ANOVA with
Bonferroni post hoc analysis. C: **P < 0.01 vs. vehicle control, unpaired Student t test.
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activated GcgR in age-matched FGF21-deficient (FGF212/2)
and WT mice (10 nmol/kg/day). Acute challenge with the
GcgR agonist increased blood glucose over a 60-min pe-
riod, regardless of genotype (Supplementary Fig. 2A).
Chronic GcgR activation in WT mice prevented body
weight accrual in mice switched to HFD on day 0 (Fig. 6A);
however, this effect was ablated in mice deficient for
FGF21 (Fig. 6B). Chronic GcgR activation also prevented
fat mass accumulation in WT mice (Fig. 6C), but not in
FGF212/2 mice (Fig. 6D). Lean mass was slightly, but
significantly, reduced in WT mice, but not in FGF212/2
mice (Fig. 6E and F). Food intake did not differ between
genotype or treatment groups (Fig. 6G), consistent with
the previous reports that GcgR activation may pre-
dominantly affect chronic energy balance via modulation
of EE (reviewed in 23,24). Consistent with the effects in
DIO WT mice (Fig. 4), chronic GcgR activation triggered
a robust increase in hepatic expression and plasma FGF21
of WT mice, whereas, predictably, FGF21 levels in
FGF212/2 mice were not detectable (Supplementary Fig.
2B and C).
Increased EE in response to GcgR activation requires
FGF21. To evaluate the direct contribution of FGF21 to
GcgR-induced effects on EE, we next treated WT and
FGF212/2 mice inside an indirect calorimeter. After 24 h
of acclimation, WT and the FGF212/2 mice were injected
FIG. 5. Glucagon as an FGF21 secretagogue. Plasma FGF21 concentration (A) in response to acute GcgR activation (n = 8; 10 nmol/kg IUB288).
Hepatic FGF21 expression (B) and plasma FGF21 concentration (C) after 18 days of vehicle (PBS, closed bars) or 10 nmol/kg/day IUB288 (open
bars) in 2-h fasted, HFD-fed mice (n = 4–5). Relative FGF21 expression (D) and secretion (E) in isolated primary hepatocytes from WT and GcgR
knockout (GcgR2/2) mice after 9.5 and 25 h glucagon treatment, respectively. Relative FGF21 expression in cultured H4IIE cells (F) after 120 min
GcgR activation (0.133 nmol/mL IUB288). Plasma FGF21 concentration (G) and area under the curve (AUC) analysis (H) after glucagon challenge
(1 mg) in human subjects. Data from A–C obtained in 11-month-old male C57Bl/6J mice maintained on HFD for 9 months. All data are represented
as mean 6 SEM. A and G: *P < 0.05; **P < 0.01; ***P < 0.001 vs. vehicle control, two-way ANOVA with Bonferroni post hoc analysis. B, C, F, and
H: *P < 0.05; ***P < 0.001 vs. vehicle control, unpaired Student t test. D and E: Sigmoidal dose-response best fit (with variable slope).
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with IUB288 (10 nmol/kg/day) or vehicle. WT mice in-
creased EE in response to chronic GcgR agonism (Fig.
7A and C), whereas FGF212/2 mice were unaffected by
the treatment (Fig. 7B and D). The changes in EE ob-
served in WT mice were associated with an increase in
spontaneous locomotor activity, whereas no effects on
locomotor activity were observed in FGF212/2 mice
(Fig. 7E and F).
Glucose and lipid metabolism changes caused by
chronic GcgR activation partially require FGF21.
Chronic GcgR agonism potentiates hepatic and adipocyte
lipolysis while reducing plasma cholesterol (23). In-
terestingly, chronic GcgR activation lowered circulating
cholesterol in WT mice, but not in FGF212/2 mice (Fig.
8A). Liver triglycerides were unaffected in either genotype
(Fig. 8B). The effects of GcgR agonism on plasma trigly-
cerides (Fig. 8C) and NEFAs (Fig. 8D) were potentiated in
FGF212/2 mice.
The hyperglycemia induced by chronic GcgR agonism
in WT mice was blunted in FGF212/2 mice (Fig. 8E).
Furthermore, chronic GcgR activation induced glu-
cose intolerance in both WT and FGF212/2 mice as com-
pared with matched vehicle-treated controls (Fig. 8F
and G). Interestingly, vehicle-treated FGF212/2 mice
exhibited better glucose tolerance than vehicle-treated
WT mice, as assessed by intraperitoneal glucose chal-
lenge (Fig. 8E and F). Taken together, these data
suggest that FGF21 is required for some, but not all,
GcgR-mediated effects on glucose and lipid metab-
olism.
FIG. 6. Energy balance during chronic GcgR activation in FGF212/2 mice. Body weight, fat mass, lean mass, and food intake of WT (A, C, E, and G)
and FGF212/2 (B, D, F, and H) mice during 20 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment. All
treatments were conducted in 12-week-old male littermates maintained on standard chow diet until day 0 and then switched to HFD upon initiation
of GcgR activation. All data are represented as mean 6 SEM; n = 12–16. *P < 0.05; **P < 0.01; ***P < 0.001 vs. genotype-specific vehicle control,
two-way ANOVA with Bonferroni post hoc analysis.
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DISCUSSION
Glucagon is an integral component of the adaptive re-
sponse to fasting in mammals, stimulating hepatic glucose
production while concomitantly liberating lipid energy
stores to maintain energy homeostasis. However, the
molecular properties of native glucagon (20,21) have his-
torically made detailed investigation of this hormone an
arduous task. Here we report the discovery of a long-
acting, soluble, and highly selective GcgR agonist
(IUB288). We have successfully used this acylated gluca-
gon agonist for chronic activation of GcgR signaling in vivo
as a means to probe glucagon biology. Data from these
studies suggest that chronic GcgR agonism suppresses
plasma cholesterol while stimulating hyperglycemia and
fat mass loss. Chronic activation of GcgR also elevated
hepatic FGF21 expression and secretion. Genetic deletion
identified FGF21 as an essential mediator for the majority
of glucagon’s long-term metabolic effects.
Development of a potent, soluble, long-acting, and
selective GcgR agonist. The GcgR agonist IUB288 is
characterized by several important substitutions, result-
ing in a potent, soluble, long-acting, and selective GcgR
agonist. The aib at position 2 is used to minimize pro-
teolytic degradation by dipeptidyl peptidase-4, a factor
that is of increased importance given its extended
duration of action. Substitution of the native Thr with Ile
at position 7 maximizes GcgR selectivity by lessening
potency at the GLP-1 receptor. The acylation at position
10 with a linear dipeptide of g-Glu capped with a C16
fatty acid provided the optimal aqueous solubility and
suitability for once-a-day administration as a subcu-
taneous injection. Aib16 stabilizes the backbone of the
peptide, maximizing receptor potency and chemical sta-
bility by elimination of the native Asp-Ser sequence,
which is prone to chemical rearrangement. This single
change is of utmost importance in minimizing the pro-
pensity to form an amyloid-like structure. The Arg to Ala
substitution at position 18 minimizes potential degrada-
tion, given the propensity of dibasic amino acids to
plasma proteolysis. Finally, the change of Asn28 to Asp
increases the chemical stability of the peptide and further
enhances aqueous solubility. In sum, these augmenta-
tions result in a highly potent and selective agonist with
dramatically extended bioavailability. The liver and kid-
neys rapidly clear circulating native glucagon (25,26).
Reports from humans and dogs suggest that the half-life
of this hormone is 5–6 min (26,27). Thus, it can be ap-
proximated that our GcgR agonist displays a mean esti-
mated terminal elimination half-life that is 63-fold longer
than that of native glucagon.
FIG. 7. EE during chronic GcgR activation. Dynamic and cumulative EE and locomotor activity of WT (A, C, and E) and FGF212/2 (B, D, and F)
mice during 72 h of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment. All treatments were conducted in 12-week-
old male littermates maintained on standard chow diet. IUB288 or vehicle administered daily, 2 h prior to dark phase. P values of A–C denote main
effect of treatment vs. vehicle control by two-way ANOVA. All data are represented as mean 6 SEM; n = 6. E: **P < 0.01 vs. genotype-specific
vehicle control, two-way ANOVA with Bonferroni post hoc analysis.
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Glucagon and lipidemia. A growing body of evidence
suggests that glucagon represents a relevant regulator of
lipid metabolism. Mechanistically, it has been suggested that
glucagon signaling may suppress expression of HMGCR
(28), the rate-limiting enzyme in cholesterol synthesis. Al-
though we observed decreased HMGCR in WT mice, it is
important to note that the decreased cholesterolemia in WT
mice was not observed in mice lacking FGF21.
GcgR agonism stimulates body and fat mass loss in
DIO mice. Studies over the past five decades have
reported glucagon-stimulated body weight loss in both
humans (29) and rodents (30). However, this phenomenon
received limited attention until we and others recently
reported potent body weight–lowering effects of novel
single-molecule coagonists combining GLP-1 and glucagon
agonism (7,8). Results from our study suggest that gluca-
gon action stimulates a loss of body mass that is primarily
a consequence of decreased fat mass, although a subtle
decrease in lean mass was observed in some experiments.
Multiple mechanisms for glucagon-stimulated body weight
loss have been put forth, including altered energy balance
(reviewed in 23,24). Studies described herein suggest that
increased EE may be the predominant physiological
mechanism for GcgR-induced body weight loss.
FIG. 8. Lipidemia and glycemia during chronic GcgR activation. Liver triglyceride (B) and plasma cholesterol (A), triglyceride (C), and NEFA (D)
concentrations of WT and FGF212/2 mice after 20 days of vehicle (PBS, closed symbols) or 10 nmol/kg/day IUB288 (open symbols) treatment (n =
4–6). Ad libitum blood glucose (E) of WT and FGF212/2 mice on day 19. Glucose tolerance (F) (as assessed by 1.5 g/kg intraperitoneal glucose
challenge) and area under the curve analysis (G) of WT (squares) and FGF212/2 (circles) mice after 19 days of vehicle (PBS, closed symbols) or 10
nmol/kg/day IUB288 (open symbols) treatment (n = 12–16). All treatments conducted in 12-week-old male littermates maintained on standard
chow diet until day 0 and then switched to HFD upon initiation of GcgR activation. All data are represented as mean 6 SEM. *P< 0.05; **P < 0.01;
***P < 0.001 vs. genotype-specific vehicle control, two-way ANOVA with Bonferroni post hoc analysis. F: **P < 0.01; ***P < 0.001 vs. WT vehicle
control, two-way ANOVA with Bonferroni post hoc analysis.
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Glucagon-stimulated negative energy balance is
leptin independent. The rapid and considerable body
and fat mass loss concomitant to increased EE resembled
the consequences of increased leptin signaling. To test the
hypothesis that GcgR signaling enhances leptin signaling
and/or sensitivity, we assessed the effect of chronic GcgR
agonism in a model lacking leptin signaling (db/db mice).
Contrary to our initial hypothesis, our data suggest that
chronic GcgR agonism stimulates body weight loss and
increases core temperature independent of leptin signal-
ing. However, unlike the further impaired glucose toler-
ance observed in DIO and chow-fed mice, GcgR-activated
db/db mice displayed an unexpected enhancement in in-
sulin action.
Glucagon and FGF21. These observations led us to in-
vestigate regulators of EE that may also represent down-
stream targets of glucagon signaling. Our data support the
hypothesis that glucagon-stimulated loss of body fat may
be mediated through FGF21. We find that both native
glucagon and our GcgR agonist increase FGF21 secretion
in rodents and humans. Importantly, this effect is retained
in isolated primary hepatocytes from WT mice, but not
GcgR knockout mice, suggesting that GcgR signaling in
hepatocytes directly stimulates FGF21 expression and se-
cretion. Our studies also highlight a role for FGF21 in the
majority of effects triggered by chronic glucagon action.
Using FGF212/2 mice, we discovered that FGF21 is es-
sential for, and may directly mediate, glucagon regulation
of body weight, fat mass, and plasma cholesterol. FGF21 is
also essential for the increased EE observed during
chronic GcgR agonism that is coupled with increased lo-
comotor activity. This increase in activity is particularly
pronounced in the light phase. Although much is known
concerning GcgR agonism and EE, its effect on locomotor
activity is not well described. Though consistent with an
increased overall EE (23,24), our findings are in direct
conflict with a prior report (31) and, as such, deserve
continued investigation. Importantly, these effects are
observed during chronically increased GcgR agonism.
Conversely, the acute effects of glucagon action on gly-
cemia are still observed in the absence of FGF21. Taken
together, our results suggest that glucagon signaling stim-
ulates FGF21 expression and secretion in order to achieve
its long-term effects on energy and lipid and glucose me-
tabolism.
FGF21 and glucose homeostasis. These studies un-
expectedly suggest that GcgR-induced hyperglycemia is
blunted in mice lacking FGF21. FGF21 pharmacology
reduces hyperglycemia, dyslipidemia, and plasma gluca-
gon in diabetic mice and nonhuman primates (9). These
effects were accompanied by increased insulin secretion
and sensitivity (32), building upon a prior body of work
detailing the antidiabetic effects of FGF21 (9,33–36). It is
possible that the explanation for this discrepancy lies in an
off-target effect of our agonist or uncoupling of the glu-
cagon-FGF21 axis at the level of glucose regulation.
However, a deeper understanding of the multiple and
complex roles of FGF21 will be required to reconcile all
available findings and pave the way for optimal selection
of potential therapeutic strategies.
In summary, we report a mechanism linking two of
today’s most promising target pathways for the treatment
of diabetes and obesity: glucagon and FGF21. This link
appears to be liver-cell autonomous and conserved
through species. Our discovery sheds new light on the
emerging suitability of key fasting response elements as
target pathways for the treatment of metabolic disease and
may also explain the well-known wasting syndrome ob-
served in patients suffering from glucagon-producing
tumors (37). Future studies, including GcgR loss of func-
tion, will allow us to further dissect the detailed molecular
interactions connecting glucagon and FGF21 action and
may provide additional drug targets for the treatment of
both cancer-related wasting syndromes and diet-induced
metabolic diseases such as obesity and type 2 diabetes.
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